WHO WOULD BENEFIT THE MOST FROM OMONTYS RECALL AND 3 MYSTERY DEATHS?
Amgen has been preparing for competition, however, from new meds like Omontys and from future biosimilar versions of its own brands. The company inked an exclusive, 7-year deal with the leading dialysis provider, DaVita, and a 3-year, non-exclusive arrangement with Fresenius (which happens to have participated in clinical trials of Omontys, also known as peginesatide).
"JUST SAYIN"!!! These deals were cut prior to the recall??